Millennium Medical Devices Signs an Exclusive Distribution Agreement with CDx Diagnostics to Distribute the DermCDx™ Skin Cancer Test Kit Primary Care Physicians will soon be able to test for basal cell carcinoma, the most common cancer in the US
GARDEN CITY, N.Y., Feb. 20, 2014 /PRNewswire/ -- Millennium HealthCare Inc. (OTCBB: MHCC) today announced that its subsidiary, Millennium Medical Devices LLC, has signed an exclusive agreement with CDx Diagnostics for distribution of DermCDx™ , a brush biopsy test kit that is used to confirm suspected basal cell carcinoma (BCC), the most common cancer in the US. DermCDx is a minimally invasive test that combines a patented brush biopsy sampling instrument with computer-assisted three dimensional laboratory analysis. It is designed to allow primary care physicians to easily confirm suspected BCC resulting in expedited referral to a dermatologist for treatment. According to the American Academy of Dermatology, basal cell carcinoma (BCC) is the most common form of skin cancer. With over 2 million new cases diagnosed each year it is also the most common cancer in the United States. While this type of skin cancer usually grows slowly, early diagnosis and treatment is important because it can grow both wide and deep, destroying much skin tissue and bone, resulting in both disfigurement and loss of function. "We developed DermCDx™ for use by the primary care physician to facilitate the earlier diagnosis of basal cell carcinomas, allowing for earlier referral and treatment by the dermatologist" said Dr. Drore Eisen, MD, DDS, Medical Director of CDx Diagnostics.
"We are pleased to expand our relationship with CDx Diagnostics and add a minimally-invasive patented test that can be used by primary care physicians for the early detection of cancer" said Dominick Sartorio, CEO of Millennium. The company continues to add products to its Medical Device business that can be used on a daily basis by primary care physicians."
About Millennium HealthCare Inc.
Millennium HealthCare Inc. through its wholly owned operating subsidiaries provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services and practice development and management services.
About CDx Diagnostics
CDx Diagnostics (www.CDxDiagnostics.com) is the leader in the detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. The CDx tests are primarily used to help prevent cancer before it can start by identifying still-harmless dysplasia (precancer), and are also used to identify early stage cancers when they can be most easily cured. Clinicians use CDx patented minimally invasive brush biopsy instruments to collect a wide-area, full thickness tissue specimen of a suspect lesion. This unique tissue specimen is then subjected to specialized, three-dimensional computer-assisted laboratory analysis. These life saving tests are nationally available to gastroenterologists, otolaryngologists, primary care physicians, oral surgeons, periodontists, and dentists.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains certain statements that may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
SOURCE Millennium HealthCare Inc.